


Vaccines and Related Biological Products Advisory Committee Meeting

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.

COVID-19 epidemiology in children and adolescents ages 6 months–17 years

Katherine E. Fleming-Dutra, MD
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
June 14, 2022



cdc.gov/coronavirus

Overview

- COVID-19 incidence and burden
- Emergency department visits
- Hospitalization rates and severity
- COVID-19-associated mortality
- Multisystem Inflammatory Syndrome in Children (MIS-C)
- Post-COVID conditions
- Other impacts of the pandemic on children and families



6 months–4 years



5–11 years



12–17 years




Currently eligible for COVID-19
vaccination


COVID-19 incidence and burden



Trends in number of COVID-19 cases in the United States among persons of all ages



Trends in number of COVID-19 cases in the United States among persons of all ages




Trends in number of COVID-19 cases in the United States among persons of all ages




COVID-19 weekly cases per 100,000 population among children ages 0–17 years by age group — United States

March 1, 2020–June 7, 2022




COVID-19 weekly cases per 100,000 population among children ages 0–17 years by age group — United States

March 1, 2020–June 7, 2022



Seroprevalence of infection-induced SARS-CoV-2 antibodies among all ages — National Commercial Lab Seroprevalence Study

September 2021–February 2022




Shading indicates confidence intervals for each trend line.

Source: Clarke K, Kim Y, Jones J et al. Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Estimation Using Commercial Laboratory Specimens: How Representative Is It of the General U.S. Pediatric Population? (April 26, 2022). Available at SSRN: <https://ssrn.com/abstract=4092074> or <http://dx.doi.org/10.2139/ssrn.4092074>

COVID-19-associated emergency department (ED) visits



Weekly percent of emergency department visits diagnosed with COVID-19 among children ages 1–17 years, National Syndromic Surveillance Program May 3, 2020–May 14, 2022



Dashed line, on December 19, 2021, represents the first date when >50% of nationally sequenced SARS-CoV-2 specimens were Omicron variant. Data contains emergency department visits from NSSP ED data feeds consistently reporting data from 2020-2022. The data contains visits with an ICD-10 or SNOMED code for COVID-19.


COVID-19-associated hospitalizations

Burden and severity of disease




COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET

March 2020 – March 2022




Cumulative COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET

March 2020 – March 2022



Rates of monthly COVID-19-associated hospitalizations by vaccination status among children and adolescents 5–17 years, COVID-NET

June 2022 – March 2022



Percent of children ages 6 months–17 years with COVID-19 associated hospitalization with at least one underlying health condition by surveillance platform


Age group	COVID-NET ^{1, 2} March 2020 – March 2022	New Vaccine Surveillance Network ³ March 2020 – April 2022
6 months–4 years	49%	46%
5–11 years	67%	68%
12–17 years	68%	60%

1. COVID-NET data. Accessed May 21, 2022, reflecting data from March 2020–March 2022.

2. Shi DS, Whitaker M, Marks KJ, et al. Hospitalizations of Children Aged 5-11 Years with Laboratory-Confirmed COVID-19 – COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep 2022;71:574-581. DOI: <http://dx.doi.org/10.15585/mmwr.mm7116e1>

3. New Vaccine Surveillance Network. Preliminary data as of May 25, 2022, reflecting data from March 2020–April 2022

Severity of COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET, December 19, 2021 – March 31, 2022 (Omicron)



BiPAP: bilevel positive pressure, CPAP: continuous positive pressure


Source: COVID-NET data. Accessed May 21, 2022.

COVID-19-associated hospitalizations

Comparisons to other pediatric infectious diseases



Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children, FluSurv-NET and COVID-NET, 2017–2022




— Influenza Oct 2017–Apr 2018
 - - - Influenza Oct 2021–Apr 2022

..... Influenza Oct 2018–Apr 2019
 — COVID-19 Oct 2020–Sep 2021

- - - Influenza Oct 2019–Apr 2020
 — COVID-19 Oct 2021–Apr 2022

— Influenza Oct 2020–Apr 2021

Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children, FluSurv-NET and COVID-NET, 2017–2022



— Influenza Oct 2017–Apr 2018

- - - Influenza Oct 2021–Apr 2022

..... Influenza Oct 2018–Apr 2019

— COVID-19 Oct 2020–Sep 2021

- - - Influenza Oct 2019–Apr 2020


— COVID-19 Oct 2021–Apr 2022

— Influenza Oct 2020–Apr 2021


Among children ages 6 months–4 years

- Oct 2020 – Sep 2021 COVID-19 hospitalization rates were lower than influenza hospitalization rates during pre-pandemic influenza seasons
- Oct 2021 – Apr 2022 COVID-19 hospitalization rates were as high or higher than influenza hospitalization rates during all influenza seasons

Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children, FluSurv-NET and COVID-NET, 2017–2022



Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children, FluSurv-NET and COVID-NET, 2017–2022



Among adolescents ages 12–17 years COVID-19 hospitalization rates in both years were higher than influenza hospitalization rates during all influenza seasons

Other Pediatric Vaccine Preventable Diseases: Hospitalizations per Year Prior to Recommended Vaccines

	Hepatitis A ¹	Varicella ² (Chickenpox)	Vaccine-type Invasive Pneumococcal Disease ³	COVID-19 ⁴
Age	5–14 years	0–4 years	0–4 years	6 months–4 years
Time period	2005	1993–1995	1998–1999	Year 1: April 2020–March 2021 Year 2: April 2021–March 2022
Hospitalization Burden (Annual rate per 100,000 population)	<1	29-42	40 ⁵	Year 1: 29.8 Year 2: 89.3

¹ <https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5603a1.htm>

² Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. *Pediatrics*. 2004;114(3):786-792. doi:10.1542/peds.2004-0012

³ Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. *MMWR Morb Mortal Wkly Rep*. 2005 Sep 16;54(36):893-7. PMID: 16163262.


⁴ COVID-NET data, Accessed May 21, 2022.

⁵ Vaccine-type invasive pneumococcal disease annual rate for children <5 years in 1998-1999 was 80 per 100,000, of which about 50% were hospitalized.


COVID-19-associated mortality




COVID-19 deaths in children and adolescents by age based on death certificate data, National Center for Health Statistics, January 1, 2020–May 11, 2022



COVID-19 deaths in children and adolescents by age based on death certificate data, National Center for Health Statistics, January 1, 2020–May 11, 2022



COVID-19 deaths in children and adolescents by age based on death certificate data, National Center for Health Statistics, January 1, 2020–May 11, 2022



COVID-19 is a leading cause of death among children and adolescents ages 1–19 years

March 1, 2020–April 30, 2022

Age group	Rank of COVID-19 among causes of death
1–4 years	5
5–9 years	5
10–14 years	4
15–19 years	4

Based on death certificate data from the National Center for Health Statistics. COVID-19 based on cumulative total incidence of COVID-19 deaths from March 1, 2020-April 30, 2022.

Source: Flaxman S, Whittaker C, Semenova E et al. Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States. medRxiv 2022.05.23.22275458; doi: <https://doi.org/10.1101/2022.05.23.22275458>

Pediatric vaccine preventable diseases: Deaths per year in the United States prior to recommended vaccines

	Hepatitis A ¹	Meningococcal (ACWY) ²	Varicella ³	Rubella ⁴	Rotavirus ⁵	COVID-19 ⁶
Age	<20 years	11–18 years	5–9 years	All ages	<5 years	6 months – 4 years
Time period	1990–1995	2000–2004	1990–1994	1966–1968	1985–1991	Jan 2020–May 2022
Average deaths per year	3	8	16	17	20	86

¹Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. *J Infect Dis* 2008; 197:1282–8.

²National Notifiable Diseases Surveillance System with additional serogroup and outcome data from Enhanced Meningococcal Disease Surveillance for 2015-2019.

³Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. *J Infect Dis*. 2000;182(2):383-390. doi:10.1086/315714

⁴Roush SW, Murphy TV; Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. *JAMA* 2007; 298:2155–63.

⁵Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. *J Infect Dis*. 1996 Sep;174 Suppl 1:S5-11.

⁶<https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-Counts-by-Age-in-Years/3apk-4u4f/data>. Accessed May 14, 2022

Multisystem Inflammatory Syndrome in Children (MIS-C)



Multisystem Inflammatory Syndrome in Children (MIS-C)

- Severe illness in persons ages 0–20 years characterized by fever, multisystem organ involvement, laboratory evidence of inflammation, and SARS-CoV-2 infection with no alternative plausible diagnosis
- Occurring 2-6 weeks after acute SARS-CoV-2 infection ¹
 - 60–70% of patients are admitted to intensive care ^{2, 3, 4}
 - 1–2% die ^{2, 3, 4}


1. https://www.cdc.gov/mis/mis-c/hcp/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmis%2Fhcp%2Findex.html. Accessed June 7, 2022.

2. Feldstein LR, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325(11):1074-1087. doi:10.1001/jama.2021.2091

3. Belay ED, et al. Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic [published online ahead of print, 2021 Apr 6]. JAMA Pediatr. 2021;e210630. doi:10.1001/jamapediatrics.2021.0630

4. Miller AD, Zambrano LD, Yousaf AR, Abrams JY, Meng L, Wu MJ, Melgar M, Oster ME, Godfred Cato SE, Belay ED, Campbell AP; MIS-C Surveillance Authorship Group. Multisystem Inflammatory Syndrome in Children-United States, February 2020-July 2021. Clin Infect Dis. 2021 Dec 5:ciab1007. doi: 10.1093/cid/ciab1007. Epub ahead of print. Erratum in: Clin Infect Dis. 2022 Apr 27;; PMID: 34864955; PMCID: PMC8689703.

Daily MIS-C and COVID-19 cases reported to CDC (7-day moving average), onset February 19, 2020–May 21, 2022




MIS-C cases are among individuals ages <21 years. COVID-19 cases reflect all cases reported to CDC (among individuals of all ages). The grayed-out area on the right side of the figure represents the most recent 6 weeks of data, for which reporting of MIS-C cases is still incomplete. Date of onset was missing for 1 of the 8,525 cases.

<https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance>. Accessed June 7, 2022.

Weekly MIS-C case counts among persons ages 0–20 years by age group (N=8,525)

February 1, 2020 – May 31, 2022

Age groups (years) ■ 0-5 mos ■ 6mos-4 years ■ 5-11 years ■ 12-17 years ■ 18-20 years




CDC Data. Age is missing for 1 case

Weekly MIS-C case counts among persons ages 0–20 years by age group (N=8,525)

February 1, 2020 – May 31, 2022


Age groups (years) ■ 0-5 mos ■ 6mos-4 years ■ 5-11 years ■ 12-17 years ■ 18-20 years



CDC Data. Age is missing for 1 case

MIS-C patients by race & ethnicity for children and adolescents ages 6 months–17 years by age group

February 1, 2020 – May 31, 2022



Age is missing for 1 case.

Source: CDC data. Accessed June 7, 2022

Post-COVID Conditions in Children



Post-COVID conditions in children

- **Post-COVID conditions in children**
 - Appear to be less common in children than in adults
 - A national survey in the UK found **7-8%** of children with COVID-19 reported continued symptoms >12 weeks¹
 - Can appear after mild to severe infections and after MIS-C
- **Most common symptoms:** Similar to adults and include fatigue, headache, insomnia, trouble concentrating, muscle and joint pain, and cough ^{2,3}
- **Impact on quality of life:** Limitations of physical activity, feeling distressed about symptoms, mental health challenges, decreased school attendance/participation²

¹Office for National Statistics United Kingdom. (2021) Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Retrieved on September 17, 2021 from Office for National Statistics' website.

<https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021>

²Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. *Acta Paediatr.* 2021;110(7):2208-2211. doi:10.1111/apa.15870.


³Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. *Lancet Child Adolesc Health* 2021; 5: 708–18.

<https://www.thelancet.com/action/showPdf?pii=S2352-4642%2821%2900198-X>

Other impacts of the COVID-19 pandemic on children and families



COVID-19 related K-12 school disruptions by week, August 2, 2021 – May 30, 2022




Data from burbio: <https://cai.burbio.com/school-opening-tracker/>. Accessed June 7, 2022.

* A COVID-19 related school disruption is defined as a school moving away from regular in-person instruction caused in some way by the pandemic

Percent of parents who say in the past year, they or another adult in their household left a job or changed work schedules to take care of their children

July 15, 2021–August 2, 2021



Percent of parents who say in the past year, they or another adult in their household left a job or changed work schedules to take care of their children

July 15, 2021–August 2, 2021

Total parents 39%

Parent to child under age 5 years 48%

Parent to child ages 5-11 years 45%

Parent to adolescent ages 12-17 years 33%

Parent age

18-39 years 44%

40 years and older 34%

Race/Ethnicity

Black 53%

Hispanic 44%

White 32%

Household income

<\$40K 51%

\$40K-\$89.9K 35%

\$90K or more 35%

Other indirect impacts of COVID-19 pandemic on children



- Worsening of mental or emotional health



- Widening of existing education gaps



- Decreased physical activity and increased body mass index (BMI)



- Decreased healthcare utilization



- Decreased routine immunizations



- Increase in Adverse Childhood Experiences (ACEs)

Conclusion



Summary: COVID-19 epidemiology in children and adolescents ages 6 months–17 years


- As of June 7, 2022, COVID-19 has caused >13.1 million cases among children and adolescents ages 0–17 years
- Omicron surge led to the highest numbers of COVID-19 cases, emergency department visits, and hospitalization rates seen during the pandemic

Summary: COVID-19 epidemiology in children and adolescents ages 6 months–17 years

- Children and adolescents are at risk of severe illness from COVID-19
 - More than half of hospitalized children ages 6 months–4 years had no underlying conditions
 - During Omicron predominance, COVID-19 associated hospitalizations among children ages 6 months–4 years have similar or increased severity compared to older children and adolescents
 - Burden of COVID-19 hospitalization is similar to or exceeds that of other pediatric vaccine preventable diseases
- COVID-19 pandemic continues to have significant impact on families and increases disparities

Acknowledgements

- ACIP COVID-19 Workgroup Team: Sara Oliver, Evelyn Twentyman, Monica Godfrey, Danielle Moulia, Megan Wallace, Lauren Roper, Kate Woodworth
- Epidemiology Task Force and Division of Viral Diseases
 - Vaccine Effectiveness Team: Ruth Link-Gelles, Tamara Pilishvili
 - COVID-NET: Fiona Havers, Chris Taylor, Rebecca Woodruff, Kristin Marks, Kadam Patel, Michael Whitaker, Huong Pham, Jenny Milucky, Onika Anglin, Dallas Shi
 - Natural History Team: Jefferson Jones, Kristie Clarke, Sharon Saydah
 - MIS-C unit: Angie Campbell, Laura Zambrano, Allison Miller
 - NVSN: Heidi Moline, Meredith McMorrow, Ariana Perez, Benjamin Clopper, Aaron Curns
 - Core Clinical Unit: David Siegel
- Data, Analytics and Visualization Task Force: Casey Lyons, Susan Wacaster, Kingsley Iyawe, Vaccine Data Section
- Nssp: Aaron Kite-Powell, Kelly Carey, Kathleen Hartnett, Karl Soetebier
- FluSurv-NET: Shikha Garg, Dawud Ujamaa, Miranda Delahoy
- Division of Vital Statistics, National Center for Health Statistics
- Many more...



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Additional slide footnotes

Slides 21-24: Cumulative influenza- and COVID-19-associated hospitalization rates per 100,000 children, FluSurv-NET and COVID-NET, 2017–2022

FluSurv-NET = Influenza Hospitalization Surveillance Network; COVID-NET = COVID-19-Associated Hospitalization Surveillance Network

Each season, FluSurv-NET surveillance is conducted from around October 1 of one year to around April 30 of the subsequent year. The grayed-out area on each panel indicates weeks during which FluSurv-NET surveillance was not conducted but COVID-NET surveillance was conducted. FluSurv-NET rate lines were extended beyond week 18 for ease of comparison. For the 2021–22 influenza season, data were only included through the week ending April 9, 2022, the last week for which data were available at the time of submission. The COVID-NET surveillance period of October 2020–September 2021 begins at MMWR week 40 of year 2020 and ends at MMWR week 39 of year 2021. The COVID-NET surveillance period for October 2021–April 2022 includes MMWR week 40 of 2021 through MMWR week 14 of 2022 (the week ending April 9, 2022, the last week for which data were available at the time of submission). MMWR Week 53 for year 2020 is combined with MMWR Week 52 for consistency with other years.

Slides 27-29: COVID-19 deaths in children and adolescents by age based on death certificate data, National Center for Health Statistics, January 1, 2020–May 11, 2022

The provisional counts for COVID-19 deaths are based on a current flow of mortality data in the National Vital Statistics System. National provisional counts include deaths occurring within the 50 states and the District of Columbia that have been received and coded as of the date specified. It can take several weeks for death records to be submitted to National Center for Health Statistics (NCHS), processed, coded, and tabulated. Therefore, the data may be incomplete, and will likely not include all deaths that occurred during a given time period, especially for the more recent time periods.